Spend Less Time Managing Fragmented Data, and More Time on the Analysis that Drives Results
Designed for Flexibility to Exceed Expectations for our Life Science Customers
When sourced from disparate electronic health records (EHRs), administrative claims databases, clinical data registries, and other siloed sources, real-world data (RWD) are often fragmented and difficult to work with. Your teams are moving fast to solve today’s health challenges and can’t afford to waste valuable time and resources with messy RWD that is inconsistent and cumbersome.
What can we do for you?
Complete this short form for a data feasibility assessment, or to talk to one of our experts about your needs.
Designed for Flexibility to Exceed Expectations for our Life Science Customers
Comprehensive sample size and representativeness
Access the Veradigm Network of ambulatory EHRs to bring an extensive, nationally distributed patient population to your research.
Discover deeper insights
Because the Veradigm Network of EHRs is the source of data itself, we can help you uncover insights typically found in unstructured notes, and only accessible by our team of data scientists.
Uncover a Robust View of The Patient Journey with Linkage Enabled EHR Data
While administrative claims data continues to be a trusted workhorse, new linkages to deep, clinical data give traditional real-world data a much-needed boost in horsepower. Claims data linked to EHR provides the best of all worlds: deep, rich clinical insights documented in the patient record, linked to detailed information about all costs and services found in claims data.
With Veradigm’s Real-World Data solutions, you can uncover deeper insights than you would traditionally access through either EHR or claims data alone. This allows you to reveal a more complete view of the patient journey with a rich, linkage-enabled, token agnostic dataset.
Notable case studies
Qualitative Analysis of Provider Notes on Atopic Dermatitis-Related Visits Using NLP
In a study conducted by scientists at Eli Lilly and Veradigm,1 unstructured qualitative provider notes recorded in electronic health records (EHRs) during visits with patients with atopic dermatitis (AD) were shown to rarely to document AD burden on daily functioning and quality of life.
The study demonstrates how combining defined data from EHR structured fields with NLP-extracted information from provider notes captured in unstructured fields offers potential to broaden understanding of AD impact and management.
Study from AstraZeneca and Veradigm on COPD - Blood Eosinophil Count
This retrospective cohort study, conducted by researchers from AstraZeneca and Veradigm, used data sourced from a nationwide, electronic health record platform, linked to transactional administrative claims.2
The study provides the first comprehensive evaluation of blood eosinophil count, healthcare utilization, and cost as reflected in current clinical practice across the United States.
Preventing Influenza-Related Medical Encounters (US 2018-2019 Season): A Real-World Study from Seqirus™ and Veradigm®
In a study conducted by Seqirus and Veradigm and published in Clinical Infectious Diseases,3 individuals four years and older who were vaccinated with cell culture-derived inactivated quadrivalent influenza vaccine (ccIIV4) had significantly fewer influenza-related medical encounters compared with individuals vaccinated with egg-derived inactivated quadrivalent influenza vaccines (eIIV4) during the 2018-19 flu season in the United States.
Study findings “provide further evidence supporting [cell-derived] ccIIV4 as a potentially more effective public health measure against influenza than an egg-derived equivalent.”
A Real-World Study from Amgen and Veradigm®: Early Use of Erenumab in US Clinical Practice
Early real-world use of erenumab was associated with high adherence and reductions in previously used acute and preventive medications, according to a study conducted by investigators at Amgen and Veradigm and published in Cephalalgia Reports.4
To date, the study is the largest to describe characteristics and treatment patterns of patients who initiated erenumab in US routine clinical practice.
1. Pierce EJ, Boytsov NN, Vasey JJ, et al. A qualitative analysis of provider notes of atopic dermatitis-related visits using natural language processing methods. Dermatol Ther (Heidelb) 30 May 2021; https://doi.org/10.1007/s13555-021-00553-5
2. Trudo F, Kallenbach L, Vasey J, et al. Clinical and economic burden of eosinophilic COPD in a large retrospective US cohort. Int J Chronic Ob Pulmonary Dis 2019:14:2625-2637. doi:10.2147COPD.S220009.
3. Boikos C, Fischer L, O’Brien D, et al. Relative effectiveness of the cell-derived inactivated quadrivalent influenza vaccine versus egg-derived inactivated quadrivalent influenza vaccines in preventing influenza-related medical encounters during the 2018-2019 influenza season in the United States. Clin Infect Dis 2021;ciaa1944. https://pubmed.ncbi.nlm.nih.gov/33400775/
4. Bogdanov A, Chia V, Bensink M, et al. Early use of erenumab in US real world practice. Cephalalgia Rep 31 May 2021;4. https://doi.org/10.1177/25158163211020419